This grant supports research into the neurobiological and behavioral causes of mood and psychosis disorders that emerge or worsen during menopause.
Funder: National Institutes of Health
Due Dates: February 5, 2027 (New) | March 5, 2027 (Renewal/resubmission/revision) | June 5, 2027 (New) | July 5, 2027 (Renewal/resubmission/revision) | October 5, 2027 (New) | November 5, 2027 (Renewal/resubmission/revision) | January 7, 2028 (Closing)
Funding Amounts: No budget cap; requests must reflect project needs; maximum project period of 5 years
Summary: Supports mechanistic and translational research on mood disruption and psychosis during the menopausal transition to identify future intervention targets.
Key Information: Studies must validate menopausal-transition status and investigate mechanisms at multiple levels of analysis.
This NIH R01 opportunity is administered by the National Institute of Mental Health (NIMH), with potential co-funding from the Office of Research on Women's Health (ORWH). It supports mechanistic and translational research on the onset or worsening of mood disruption, emotion dysregulation, and psychosis during perimenopause—from menstrual-cycle changes and menopause-related symptoms through early post-menopause. The goal is to identify neurobiological, behavioral, and social mechanisms and targets for future prevention or treatment.
Research interests include reproductive steroids, brain circuits, risk factors, mortality-related mechanisms, computational approaches, and neural or behavioral recording methods tied to scientific questions. Dimensional approaches and interdisciplinary teams are encouraged, including teams with lived experience of perimenopausal depression or psychosis. Mechanistic clinical trials are permitted, but trials evaluating intervention safety, efficacy, effectiveness, management, or implementation are not responsive.